CA3049689A1 - Compositions and methods for augmenting antibody mediated receptor signaling - Google Patents

Compositions and methods for augmenting antibody mediated receptor signaling Download PDF

Info

Publication number
CA3049689A1
CA3049689A1 CA3049689A CA3049689A CA3049689A1 CA 3049689 A1 CA3049689 A1 CA 3049689A1 CA 3049689 A CA3049689 A CA 3049689A CA 3049689 A CA3049689 A CA 3049689A CA 3049689 A1 CA3049689 A1 CA 3049689A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
antibody
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3049689A
Other languages
English (en)
French (fr)
Inventor
Wayne A. Marasco
Quan Karen ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3049689A1 publication Critical patent/CA3049689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3049689A 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling Abandoned CA3049689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Publications (1)

Publication Number Publication Date
CA3049689A1 true CA3049689A1 (en) 2018-08-09

Family

ID=63040120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049689A Abandoned CA3049689A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Country Status (7)

Country Link
US (2) US20220213206A1 (cg-RX-API-DMAC10.html)
EP (1) EP3576793A4 (cg-RX-API-DMAC10.html)
JP (3) JP7231549B2 (cg-RX-API-DMAC10.html)
CN (1) CN110520158A (cg-RX-API-DMAC10.html)
AU (2) AU2018215673B2 (cg-RX-API-DMAC10.html)
CA (1) CA3049689A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018145075A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031194A1 (en) * 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
WO2022241182A1 (en) * 2021-05-13 2022-11-17 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
JP6636803B2 (ja) * 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
DK3189081T3 (da) * 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
CA2978501A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
EP3535291A1 (en) * 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof

Also Published As

Publication number Publication date
JP2023036899A (ja) 2023-03-14
AU2018215673A1 (en) 2019-07-25
JP7231549B2 (ja) 2023-03-01
US20240336694A1 (en) 2024-10-10
AU2025202811A1 (en) 2025-05-08
CN110520158A (zh) 2019-11-29
JP7606501B2 (ja) 2024-12-25
EP3576793A4 (en) 2021-03-31
WO2018145075A1 (en) 2018-08-09
JP2025028191A (ja) 2025-02-28
AU2025202811A9 (en) 2026-03-05
US20220213206A1 (en) 2022-07-07
AU2018215673B2 (en) 2025-01-23
EP3576793A1 (en) 2019-12-11
JP2020505054A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
CN113286821B (zh) 靶向肿瘤的激动性cd28抗原结合分子
US20250066481A1 (en) Fc variant compositions and methods of use thereof
EP2760891B1 (en) Hybrid constant regions
EP4126946A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2022538718A (ja) 二重特異性抗体及びその調製方法、使用
CN106062206A (zh) 双特异性cd3和cd19抗原结合构建体
US20240269176A1 (en) Heterodimeric fc domain antibodies
KR20230018425A (ko) 항-cd200r1 항체 및 이의 사용 방법
KR20250129817A (ko) D-도메인 함유 폴리펩티드 및 그의 용도
CN117715934A (zh) 抗cd3构建体及其用途
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220809